About Therapeutic Vaccines
A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period.
TechNavio's analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market.
TechNavio's report, the Global Therapeutic Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Bavarian Nordic A/S.
Novartis International AG
Other Prominent Vendors
Argos Therapeutics Inc.
Celldex Therapeutics Inc.
Cytos Biotechnology AG
NewLink Genetics Corp.
TVAX Biomedical Inc.
Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders
Ongoing Development of a Large Number of Therapeutic Vaccines
Adverse Side Effects of Therapeutic Vaccines
Improved Understanding of Immunology and Immunotherapy
Increase in Mergers and Acquisitions
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Key Leading Countries
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Pipeline Analysis
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Agenus Inc.
18.1.1 Business Overview
18.1.2 Key Information
18.1.3 SWOT Analysis
18.2 Bavarian Nordic A/S
18.2.1 Business Overview
18.2.2 Business Segmentation
18.2.3 Key Information
18.2.4 SWOT Analysis
18.3 Dendreon Corp.
18.3.1 Business Overview
18.3.2 Key Information
18.3.3 SWOT Analysis
18.4 GlaxoSmithKline plc
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
18.5 Novartis International AG
18.5.1 Business Overview
18.5.2 Business Segmentation
18.5.3 Key Information
18.5.4 SWOT AnalysisOther Reports in the Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Therapeutic Vaccines Market 2013-2018 (US$ billion)
Exhibit 3: Global Therapeutic Vaccines Market by Geographical Segmentation 2013
Exhibit 4: Segmentation of Therapeutic Vaccines under Clinical Trial, by Disease 2013
Exhibit 5: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Cancer 2013
Exhibit 6: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Tropical Infectious Disease 2013
Exhibit 7: Segmentation of Therapeutic Vaccines under Clinical Trial, By Physiological Disorders 2013
Exhibit 8: Late Stage Pipeline Analysis of Therapeutic Vaccines 2013
Exhibit 9: Business Segmentation of Bavarian Nordic A/S
Exhibit 10: Business Segmentation of GlaxoSmithKline plc
Exhibit 11: Business Segmentation of Novartis International AG